DNases, Ligases, And RNA Polymerases Market (By Application: DNases, RNA Polymerase, Ligases) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

The global DNases, ligases, and RNA polymerases market was estimated at USD 611.97 million in 2021 and it is expected to surpass around USD 1.4 billion by 2030, poised to grow at a CAGR of 9.63% from 2022 to 2030.

Report Highlights

• The biopharmaceutical processing segment is expected to expand at a CAGR of 8.41% over the forecast period. 
• The mRNA production segment dominated the RNA polymerase market with a revenue share of over 75.18% in 2021. 
• North America led the market with a share of over 35.16% in 2021 and is anticipated to grow lucratively over the forecast period. 
• Asia Pacific is expected to expand at the fastest CAGR of 9.54% during the forecast period.

Increasing research and development expenditure is one of the key factors fueling market growth. Furthermore, rising biopharmaceutical production along with a focus on DNA-related innovations is expected to positively impact the global DNases market growth over the forecast period.

For instance, in June 2020, Alphazyme and Codexis entered into a strategic partnership to provide novel enzymes for diagnostics and research. DNases have continued to garner a significant market share in recent years owing to factors such as an increase in the adoption of DNA enzymes related to pharmaceuticals, which are essential for the treatment of various chronic disorders and digestive diseases. In addition, developments in the biotechnology and pharmaceutical fields, such as the introduction of genetic and protein engineering, have helped in expanding applications of enzymes, which is expected to offer lucrative growth opportunities in the forecast period.

An increase in R&D investments to develop ligases as the target for therapeutic applications in cancer is estimated to drive the segment in the forecast period. In addition, strategic activities by major manufacturers will offer lucrative growth opportunities in the projected period. Other factors augmenting segment growth include advancements in healthcare, increasing demand for modernization in the field of medical academics and life sciences, growing investments by governments to develop genomic technologies, and a surge in the demand for oligonucleotide synthesis by private and public research firms.

The COVID-19 pandemic situation has offered lucrative opportunities for RNA polymerase applications. Currently, there are over 150 vaccines and therapeutics that either use mRNA in their production processes or are based on mRNA molecules, which are being assessed for the treatment of a wide range of indications. Many mRNA vaccines are approved for emergency use in many countries across the globe.

For instance, Moderna's mRNA-1273 and BioNTech/ Pfizer BNT-162 vaccines have been approved for use across various regions globally. Moreover, there are instances of huge capital investments for the development of mRNA vaccines. For instance, in June 2021, Sanofi declared an investment of around USD 452.12 annually for its mRNA vaccines development center.

Scope of The Report

DNases Application Insights

The other applications segment dominated the market with a revenue share of over 65.04% in 2021. Other applications comprise possible treatment of cystic fibrosis, COPD, and asthma; prediction of common diseases; and forensic applications. Recombinant human DNase1 is a widely used mucolytic agent in individuals with cystic fibrosis. By cleaving DNA, DNase1 reduces the abnormal thickness of cystic fibrosis mucus in vitro and enhances lung function and airway clearance in cystic fibrosis patients. Moreover, enzyme DNases are used in forensic applications, and the most widely utilized is HaeIII for forensic DNA analysis, which cuts DNA at the sequence 5'-GGCC-3'.

The biopharmaceutical processing segment is expected to expand at a CAGR of 8.41% over the forecast period. This is attributed to the factors such as an increase in the adoption of DNA enzymes related to pharmaceuticals, which are essential for the treatment of various chronic diseases and digestive disorders. In addition, developments in the biotechnology and pharmaceutical fields, such as the introduction of genetic and protein engineering, have helped in expanding applications of enzymes, which is expected to offer lucrative growth opportunities in the forecast period.

Ligases Application Insights

The other applications segment held the largest share of over 55.03% in 2021. Other applications include in vitro gene manipulation, analysis of protein-protein interactions and DNA sequencing, and catalyzing the formation of phosphodiester bonds in DNA & RNA molecules. The DNA ligase from T4 bacteriophage is one of the widely used enzymes in molecular biology. DNA ligases are used for various applications in biotechnology and molecular biology. Many times, they have been used in the detection of mutation using ligation chain reaction and construction of recombinant DNA molecules.

The oligonucleotide segment is expected to witness significant growth in the coming years. Oligonucleotide synthesis, the biochemical synthesis of nucleic acids, has emerged as an essential tool in the area of molecular biology. Synthetic oligonucleotides have been used in several applications such as diagnosis of infectious and genetic diseases, disease treatment, and new drug discovery. With 12 oligonucleotide drugs moving to the ligases market in 2021 and more than hundreds in preclinical development and clinical trials, the most recent stage in the development of a product in oligonucleotide manufacturing poses a cost liability to manufacturers.

RNA Polymerase Application Insights

The mRNA production segment dominated the RNA polymerase market with a revenue share of over 75.18% in 2021. The year 2020 was a breakout year for mRNA technology platforms, with the unveiling and extensive usage of mRNA vaccines for coronavirus. The applications of RNA, both in clinical R&D and basic research, have expanded after developments in the field of molecular biology have considerably improved the in vitro reliability of such molecules. At present, there are over 150 vaccines and therapeutics that either use mRNA in their production processes or are based on mRNA molecules, which are being assessed for the treatment of a wide range of indications.

Many mRNA vaccines for COVID-19 are approved for emergency use in many countries across the globe and there are increasing capital investments for the development of mRNA vaccines. For instance, in June 2021, Sanofi declares an investment of around USD 452.12 annually for its mRNA vaccines development center.

The other applications segment is expected to register a CAGR of 8.5% in the forecast period. RNA polymerase plays a key role in transcription, cDNA synthesis, and synthesis of antisense RNA and dsRNA. RNA polymerase is the key transcription enzyme, and transcription begins when RNA polymerase binds to a supporter sequence near the beginning of a gene.

Regional Insights

North America led the market with a share of over 35.16% in 2021 and is anticipated to grow lucratively over the forecast period. The factors such as the increase in the adoption of DNA enzymes that can be used for drug development and are essential for different therapeutic regimes to treat chronic disorders and digestive diseases. Furthermore, RNA polymerases are in high demand after the COVID-19 pandemic in the U.S. due to the demand for mRNA vaccines. RNA polymerases are also regularly used in drug development processes for the treatment of infections caused by tuberculosis and leprosy. Moreover, many novel mRNA-based vaccines are in various stages of development for a wide variety of cancers. Increasing cases of infectious diseases will boost market growth in the forecast period.

Asia Pacific is expected to expand at the fastest CAGR of 9.54% during the forecast period. Significant developments in Japan and China for technological integration and rapid healthcare development, clinical development frameworks, and growing R&D in emerging economies such as Australia and India have created significant opportunities in the Asia Pacific, which is anticipated to boost the market growth in the region during the forecast period.

Key Players

DNases market:

• Merck KGaA/ Sigma Aldrich

• Takara Bio

• Calzyme

• Thermo Fisher Scientific

• Promega Corporation

• QIAGEN

• Agilent Technologies

• RayBiotech

• New England Biolabs

• Abnova Corporation

ligases market:

• Thermo Fisher Scientific
• New England Biolabs
• RayBiotech
• Agilent Technologies
• ABclonal Technology
• BioVision
• Promega Corporation
• MBL International
• Blirt
• MyBioSource

RNA polymerases market:

• Merck BPS Bioscience, Inc.
• Novus Biologicals
• Sino Biological, Inc.
• MyBioSource
• RayBiotech
• New England Biolabs
• Thermo Fisher Scientific
• Biorbyt
• Agilent Technologies
• Promega Corporation

Market Segmentation

Application Outlook

• DNases Application
  • Biopharmaceutical Processing
  • Other applications
• Ligases Application
  • Oligonucleotide Synthesis
  • Other Applications
• RNA Polymerase Application
  • mRNA Production
  • Other Applications

Regional Outlook

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Asia Pacific
• Japan
• China
• India
• Singapore
• Australia
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE